Clinical recommendations on who should be screened for lung cancer are based largely on how long a person smoked and the number of cigarettes they smoked. But current recommendations may need to be reviewed when it comes to African Americans who smoke, a new study suggests. In the study, only about one-third of African American smokers diagnosed with lung cancer over a 12-year period would have met the criteria for annual lung cancer screening with low-dose computed tomography (CT) laid out by the US Preventive Services Task Force (USPSTF). In contrast, more than half of white smokers diagnosed with lung cancer met…
Author: Brett Johnson
Glioblastoma Multiforme (GBM) is the deadliest and most aggressive form of brain cancer for which there is currently no cure. This often-fatal brain cancer accounts for 45% of all malignant brain tumors and 12,000 cancer diag noses per year in the United States, in addition to tens of thousands more around the globe. The average GBM patient has a survival rate of one to two years. Out of determination to improve outcomes for GBM patients, in June 2019, after years of collaboration the Global Coalition for Adaptive Research (GCAR) launched GBM AGILE – a global effort to defeat GBM…
VPAC1 biomarkers are expressed on cell surfaces in high densities at the onset of oncogenesis. When VPAC1 receptors are targeted, cancer can be diagnosed early, but specifically, it allows physicians to distinguish malignant from benign lesions. NuView’s new NV-VPAC1 technology works as a Positron Emission Tomography (PET) imaging agent for the in vivo diagnosis of breast and prostate cancer, by combining an NV-VPAC1 peptide with a medical imaging isotope, illuminating cancerous VPAC1 biomarkers for detection and removal. NV-VPAC1™ used in conjunction with a PET scan and fluorescent dye can detect and confirm the shed of cancer cells in voided urine,…
A company is changing the imaging industry with new software that far exceeds all current mammography technology. This breakthrough technology reveals the make up of the entire breast, including what dense tissue usually hides, allowing doctors to see a level of detail unparalleled to anything before. This new approach to machine learning allows both the clinician and artificial intelligence engines to see what is really there and differentiate early stage cancer and other structural abnormalities potentially smaller than 1mm. This level of detail has the potential to provide clinicians significant and critical time advantage, thereby enabling better outcomes: fewer false positives…
A new breakthrough energy-based cancer therapy has the ability to kill cancer cells with no side effects in five different cancer cell types: breast, prostate, and the pancreas. This new therapy induces rapid cell death in over 80% in just two hours. It utilizes a drug combined with a certain light wavelength to produce a chemical reaction, then injected into a cancerous tissue, which disseminates, resulting in high acidity in the cancer cells, and eventually, death. The drug mixed with their technology shows no adverse side effects and been successful at killing different types of cancer cells in their petri…
A real-time, in vivo imaging platform guides surgeons during cancer surgery. This breakthrough technology illuminates cancer cells and other diseased tissues at the molecular level, allowing surgeons to take action and better patient outcomes. Currently, there is a technological gap at the molecular level. Surgeries are being completed without being able to distinguish between healthy and cancerous tissue. This technology solves the problem, so surgeons can complete their surgeries with the ability to differentiate between tissues and have better accuracy in removing all cancerous tissue. Currently, the company is focused on breast cancer in their testings, but want to continue…
Clifford Reid is the founding CEO of Travera. Previously, Dr. Reid was the founding Chairman, President and Chief Executive Officer of Complete Genomics (NASDAQ:GNOM), a leading developer of whole human genome DNA sequencing technologies and services. Dr. Reid is on the Visiting Committee of the Biological Engineering Department at the Massachusetts Institute of Technology (MIT), a member of the MIT Corporation Development Committee, and an advisor to Warburg Pincus. He earned a S.B. in Physics from MIT, an MBA from the Harvard Business School, and a Ph.D. in Management Science and Engineering from Stanford University. Brett Johnson: So tell us…
Travera’s new technology can predict how patients will respond to hundreds of different drugs or drug combinations before the patients even take the drugs. Their new measurement tool, the Suspended Microchannel Resonator (SMR), reveals cancer cells’ responses to effective drugs faster than ever before. Travera tests on-label drugs, off-label drugs, and investigational drugs, to maximize drug quality and effectiveness for patients and to save them from unnecessary toxicity. By doing so, Travera can pinpoint the right drugs within <2 days, even though it will take many weeks to work in the patient’s body, and thus, is moving oncology from being…